Selecta Biosciences, Inc. (SELB) Shares Bought by Vanguard Group Inc.
Vanguard Group Inc. lifted its position in shares of Selecta Biosciences, Inc. (NASDAQ:SELB) by 175.5% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 217,634 shares of the company’s stock after buying an additional 138,646 shares during the period. Vanguard Group Inc.’s holdings in Selecta Biosciences were worth $4,322,000 as of its most recent SEC filing.
Other hedge funds have also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp acquired a new stake in Selecta Biosciences in the 1st quarter valued at $211,000. Goldman Sachs Group Inc. increased its holdings in Selecta Biosciences by 83.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 31,588 shares of the company’s stock valued at $452,000 after purchasing an additional 14,332 shares in the last quarter. Candriam Luxembourg S.C.A. increased its holdings in Selecta Biosciences by 306.5% in the 2nd quarter. Candriam Luxembourg S.C.A. now owns 126,000 shares of the company’s stock valued at $2,502,000 after purchasing an additional 95,000 shares in the last quarter. Trexquant Investment LP acquired a new stake in Selecta Biosciences in the 2nd quarter valued at $334,000. Finally, Schwab Charles Investment Management Inc. acquired a new stake in Selecta Biosciences in the 2nd quarter valued at $392,000. Institutional investors and hedge funds own 54.44% of the company’s stock.
Shares of Selecta Biosciences, Inc. (NASDAQ:SELB) opened at $10.23 on Friday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 9.48 and a current ratio of 9.48. Selecta Biosciences, Inc. has a 52 week low of $8.70 and a 52 week high of $25.00.
Several analysts recently issued reports on SELB shares. UBS downgraded Selecta Biosciences from a “buy” rating to a “neutral” rating in a report on Thursday, November 9th. Zacks Investment Research upgraded Selecta Biosciences from a “hold” rating to a “buy” rating and set a $10.00 target price for the company in a research note on Saturday, November 11th. Canaccord Genuity restated a “buy” rating and set a $30.00 target price on shares of Selecta Biosciences in a research note on Tuesday, November 7th. Finally, ValuEngine downgraded Selecta Biosciences from a “hold” rating to a “sell” rating in a research note on Tuesday, September 26th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. Selecta Biosciences has an average rating of “Buy” and an average target price of $25.20.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.
Receive News & Stock Ratings for Selecta Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc. and related stocks with our FREE daily email newsletter.